Gland Pharma (NSE: GLAND) Shares Surge 12% to 52-Week High of ₹2,969.90 After Strong Q1 FY27 Results
Key Points
Gland Pharma shares surged 12% to a 52-week high of ₹2,969.90.
Q1 FY27 net profit jumped 47% YoY to ₹317 crore.
US revenue rose 32%, while CDMO revenue grew 20%.
Analysts remain split as strong growth meets valuation concerns.
Gland Pharma shares jumped nearly 12% on August 11, 2026, hitting a fresh 52-week high of ₹2,969.90 after the company reported strong Q1 FY27 results. Revenue rose 19.5% year on year to ₹1,800 crore, while net profit surged 47% to ₹317 crore. Strong US sales and rising CDMO revenue supported the quarter. The sharp rise in the stock has now put the focus on whether Gland Pharma can maintain this pace of growth while supporting its higher valuation.
Gland Pharma Q1 FY27 Results: Profit Jumps 47%, Revenue Rises 20%
Gland Pharma started FY27 with a strong quarter. For the quarter ended June 30, 2026, consolidated revenue from operations rose 19.5% year on year to ₹1,800 crore, compared with ₹1,506 crore a year earlier. Net profit increased 47% to ₹317 crore. EBITDA also rose 32.8% to ₹489 crore.
Profit grew faster than revenue during the quarter, helped by better operating performance.
Why did Gland Pharma’s margins improve?
The company also reported an improvement in operating margins. EBITDA margin increased to 27.2% from 24.4% in the year-ago quarter, an improvement of about 280 basis points.
That means Gland Pharma generated more operating profit from its revenue during the quarter. The margin improvement also helped the company deliver a stronger rise in profit than sales.
The latest result follows a strong Q4 FY26. Gland Pharma had reported its highest-ever quarterly revenue and EBITDA in the March quarter, while CDMO revenue grew 28% during that period.
US Growth and CDMO Business Drive Gland Pharma’s FY27 Outlook
How important is the US market for Gland Pharma?
The US remained Gland Pharma’s largest growth market in Q1 FY27. Revenue from the US rose 32% year-on-year to ₹981 crore. Revenue from Europe also increased by about 20% to ₹395 crore.
The strong US performance helped lift overall revenue during the quarter. Gland Pharma has a large presence in complex injectables and other pharmaceutical products across global markets. Higher US sales can also support better capacity utilisation and operating leverage.
What is driving the CDMO opportunity?
CDMO revenue grew 20% year on year in Q1 FY27 and accounted for about 50% of total revenue. The business is becoming a larger part of Gland Pharma’s revenue mix and could provide better visibility as new contracts move towards commercial production.
The company also has new projects in its pipeline. According to broker research, a major CDMO project is expected to be commercialised in the second half of FY28.
Gland Pharma Growth Outlook: What Could Support the Stock?
Management’s growth outlook remains an area investors will watch closely. New CDMO contracts, complex product launches, higher capacity utilisation and the turnaround at Cenexi could support growth through FY27 and beyond.
Execution will now matter more as expectations have risen after the Q1 results. Investors will be looking for continued growth in the coming quarters. Commercial launches from the CDMO pipeline could provide another source of revenue growth if projects progress as planned.
Gland Pharma Target Price: What are Analysts Saying?
Broker views remain divided following the sharp rise in Gland Pharma shares.
- Jefferies: Buy, with a target of ₹3,350.
- Nomura: Target of about ₹3,330.
- Motilal Oswal: Target of around ₹3,080.
- Ambit Capital: Target of ₹1,940.
The wide gap between these targets reflects different views on the stock’s earnings potential and valuation. Bullish analysts expect stronger earnings and continued CDMO growth. More cautious views point to the sharp rise in the share price and the valuation investors now have to pay.
Gland Pharma Stock Forecast and Technical Analysis
Gland Pharma shares surged about 12% on August 11, 2026, reaching the ₹2,969.90 level cited as the new 52-week high. The move followed the company’s Q1 FY27 results.
The price action points to strong buying momentum in the short term. After such a sharp move, though, profit-taking can also become a risk.
Earlier technical analysis had identified a bullish structure. In May, SMIFS identified an ascending-triangle breakout and set a target of ₹2,125 to ₹2,130. The stock has since moved well above those levels.
Investors may now watch whether Gland Pharma can hold the breakout zone rather than focus only on the one-day jump.
What Does Meyka Say About Gland Pharma Stock?
Meyka’s latest available GLAND.NS analysis gives the stock a Fundamental Health Score of 66.6/100, or C+. It points to a strong balance sheet, with debt-to-equity at just 0.03 and a current ratio of 4.68.
Meyka also flags valuation concerns. Its data shows a P/E ratio of 37.38 and a price-to-book ratio of 3.71.
Meyka’s earlier technical analysis rated GLAND. BO B+ Buy and pointed to strong momentum, while also warning about overbought conditions.
Its AI stock analysis tool can help investors track valuation, technical indicators, and changing market signals. Still, investors should not treat its forecasts as guaranteed returns.
Conclusion: Can Gland Pharma Sustain the Rally?
Gland Pharma’s Q1 FY27 results provide solid support for the recent stock move. Revenue, profit, margins, US sales and CDMO revenue all increased. At the same time, the sharp rally has made valuation more demanding. The next few quarters will show whether Gland Pharma can maintain US growth, expand its CDMO business and keep margins at current levels. If execution slows, the stock could face profit-taking after its strong run.
Disclaimer:
The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)